Shenzhen - Delayed Quote CNY

Apeloa Pharmaceutical Co.,Ltd (000739.SZ)

13.95
+0.03
+(0.22%)
At close: 3:04:48 PM GMT+8
Loading Chart for 000739.SZ
  • Previous Close 13.92
  • Open 13.99
  • Bid 13.94 x --
  • Ask 13.95 x --
  • Day's Range 13.83 - 14.02
  • 52 Week Range 12.70 - 18.96
  • Volume 7,905,875
  • Avg. Volume 12,314,557
  • Market Cap (intraday) 16.312B
  • Beta (5Y Monthly) 0.56
  • PE Ratio (TTM) 15.67
  • EPS (TTM) 0.89
  • Earnings Date --
  • Forward Dividend & Yield 0.32 (2.28%)
  • Ex-Dividend Date May 23, 2024
  • 1y Target Est 19.42

Apeloa Pharmaceutical Co.,Ltd provides raw materials and intermediates to various pharmaceutical factories in the People's Republic of China and internationally. The company offers preparation products, including cardio-cerebrovascular, anti-infection, anti-tumor, anti-viral, and special drugs. It offers its products under the Tianliwei, Beshin, Yosemade, Jutai, and other brands. Apeloa Pharmaceutical Co.,Ltd was founded in 1989 and is based in Dongyang, the People's Republic of China.

www.apeloa.com

7,060

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 000739.SZ

View More

Performance Overview: 000739.SZ

Trailing total returns as of 5/14/2025, which may include dividends or other distributions. Benchmark is SSE Composite Index (000001.SS) .

YTD Return

000739.SZ
14.21%
SSE Composite Index (000001.SS)
1.56%

1-Year Return

000739.SZ
9.37%
SSE Composite Index (000001.SS)
8.21%

3-Year Return

000739.SZ
44.49%
SSE Composite Index (000001.SS)
10.36%

5-Year Return

000739.SZ
17.95%
SSE Composite Index (000001.SS)
18.59%

Compare To: 000739.SZ

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 000739.SZ

View More

Valuation Measures

Annual
As of 5/14/2025
  • Market Cap

    --

  • Enterprise Value

    13.66B

  • Trailing P/E

    15.66

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    1.40

  • Price/Book (mrq)

    2.33

  • Enterprise Value/Revenue

    1.18

  • Enterprise Value/EBITDA

    11.14

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    8.97%

  • Return on Assets (ttm)

    4.53%

  • Return on Equity (ttm)

    15.37%

  • Revenue (ttm)

    11.55B

  • Net Income Avi to Common (ttm)

    1.04B

  • Diluted EPS (ttm)

    0.89

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    3.47B

  • Total Debt/Equity (mrq)

    10.90%

  • Levered Free Cash Flow (ttm)

    310.45M

Research Analysis: 000739.SZ

View More

Company Insights: 000739.SZ

Research Reports: 000739.SZ

View More

People Also Watch